Seven life sciences companies were expected to go public this week, raking in nearly $400 million combined amid a return to bullishness for biotech IPOs. That, however, didn’t work out, as only one hopeful made it through after taking a deep discount. …read more Source: Biotech IPOs: A planned big week comes up short as […]
While 2013’s number of approved drugs fell short of 2012’s record haul, the class is likely to more than make up for that disparity in the dollar column, according to EvaluatePharma. …read more Source: Report: Biopharma’s class of 2013 is laden with blockbusters
Welcome to the latest edition of our weekly EuroBiotech Report. We lead this week on news that Neil Woodford’s much-discussed fund is starting to take shape, with a $50 million (€36.8 million) investment in Elan-spinoff Prothena among its first batch of positions. And more. …read more Source: Woodford buys $50M Prothena stake, Shire lacks ‘British […]
Polaris Partners, one of the biggest investors in biotech, is setting up a new $400 million fund. The venture group outlined the bare bolts for Fund VII in an SEC filing earlier in the week, which follows on the heels of its last $375 million fund, pieced together during lean-and-mean times back in 2011. …read […]
German giant Boehringer Ingelheim is racing to the market with an antidote to its blockbuster blood-thinner Pradaxa, securing the FDA’s coveted breakthrough therapy designation for its in-development treatment. …read more Source: Boehringer bags a ‘breakthrough’ tag for its Pradaxa antidote
One week before Cubist celebrated the FDA’s approval of Sivextro, an antibiotic that figured prominently in its $707 million buyout of a biotech named Trius, the biotech’s former CEO filed papers with the SEC outlining a $30 million raise for a new antifungal venture currently called K2 Therapeutics along with $6 million in funds to […]
AstraZeneca’s top investigators took their best case for an accelerated approval of the failed cancer drug olaparib to the FDA’s panel of outside experts on Wednesday, and they lost. …read more Source: UPDATED: FDA experts spurn AstraZeneca’s pitch for ovarian cancer drug olaparib
Affymax, which 18 months ago appeared poised for big things, is dissolving the company and will pay shareholders pennies for the shares that traded at $27 a share before patient deaths led it to pull its Omontys anemia drug from the market. …read more Source: Affymax, once a promising biotech, is dissolving
Close to a year ago Switzerland’s Basilea raised a red flag about its U.S. strategy for its antibiotic ceftobiprole, noting that the FDA’s new standard requiring two late-stage studies for a program like this could present a major hurdle. Today company execs confirmed that the regulatory path into the U.S. is closed for now. …read […]
Close on the heels of a new discovery deal this week with Roche, Versant Venture’s incubation team at Inception Sciences outlined plans this week to establish a new research team in Montreal’s biotech hub, adding a third site to Inception that will hunt down new pacts and create new biotechs for product-hungry pharma companies. …read […]
